Showing 1-9 of 9 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Implementation on the LIAISON® platform of T1D autoantibody immunoassays | Ospedale San Raffaele | Vito Lampasona | Cures | 01-October-2022 to 30-September-2025 | $432,142.46 |
| Unveiling the Relationship Between Insulin Resistance and Anti-Islet Immunity in T1D | Università degli Studi di Milano | Alessandra Petrelli | Cures | 01-January-2025 to 31-December-2025 | $100,193.80 |
| GLUT1 Inhibition in type 1 diabetes | Università Vita-Salute San Raffaele | Paolo Monti | Cures | 01-August-2024 to 30-April-2026 | $68,102.00 |
| Bio-engineering of a Vascularized Islet Organ (BioVIO) for the treatment of T1D | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-April-2022 to 30-September-2025 | $1,227,217.01 |
| Bioengineered Islet Organs to Accelerate Clinical Translation in T1D (BIO-ACT) | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-February-2026 to 31-January-2029 | $1,519,453.20 |
| Critical Quality Attributes (CQAs)-Guided Selection of GMP-Compliant iPSC Lines for β Cell Replacement Therapy | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-February-2026 to 31-January-2028 | $358,418.00 |
| Impact of NK cells on the outcome of transplantation in patients with Type 1 Diabetes | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-January-2023 to 31-December-2026 | $699,918.00 |
| Ladarixin and Antithymocyte Globulin (ATG) in New Onset Type1 Diabetes | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-February-2025 to 31-January-2028 | $996,691.00 |
| Late pre-clinical validation of safety and long-term functionality of hypoimmunogenic iPSC-derived β cells into fully humanized transgenic mouse model of Type 1 Diabetes. | Università Vita-Salute San Raffaele | Lorenzo Piemonti | Cures | 01-December-2024 to 30-November-2027 | $999,995.70 |